Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy

There are over 400 ongoing clinical trials using tumor-derived vaccines. This approach is especially attractive for many types of brain tumors, including glioblastoma, yet so far the clinical response is highly variable. One contributor to poor response is CD200, which acts as a checkpoint blockade,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Immunotherapy
Asıl Yazarlar: Xiong, Zhengming, Ampudia-Mesias, Elisabet, Shaver, Rob, Horbinski, Craig M, Moertel, Christopher L, Olin, Michael R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Future Medicine Ltd 2016
Konular:
Special Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5619161/
https://ncbi.nlm.nih.gov/pubmed/27485078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2016-0033
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller